+ Significant earnings improvement + Mobile health encounters enormous interest

Neuss, May 2, 2012 – MEDISANA reports consolidated revenue up from EUR 46.3 million to EUR 47.3 million in the 2011 financial year, despite its interest in Gimelli Laboratories Co. Ltd. (Gimelli) being con-solidated only until the end of September. The company thereby achieved a new record revenue level in its corporate history.

Operating earnings (EBIT) improved significantly, as planned. MEDISANA generated earnings before interest and tax (EBIT) of EUR -0.4 million (previous year: EUR -3.6 million). Although the cost of sales increased due to intense competition in 2011, and the functional areas’ operating expenses were up slightly, the company offset this through positive effects arising from the sale of its interest in Gimelli. Other operating expenses fell by 46.1 percent to EUR 1.1 million, and at EUR 4.3 million, other operating income was significantly higher than the previous year’s EUR 1.6 million. Consolidated earnings after tax improved significantly as a consequence, amounting to EUR -0.4 million (previous year: EUR -5.9 million), and earnings per share stood at EUR -0.05, compared with EUR -0.77 in the previous year.

The spin-off of Gimelli is also reflected in the balance sheet. Total assets fell by EUR 9.6 million to EUR 32.5 million, which, together with the almost breakeven earnings position, fed through to an in-crease in the equity ratio to 33.7 percent (previous year: 25.2 percent). With its equity capital base, as well as free credit lines and cash and cash equivalents amounting to EUR 2.8 million as of the balance sheet date, MEDISANA continues to regard itself as sufficiently financed.

Innovating home health care
MEDISANA’s focus on innovation has already proved worthwhile. Product developments in the Home of Wellness, blood glucose and Mobile Health areas have been taken up very positively on the markets. In particular, mobile health products from the VitaDock series are already encountering major attention from the media and industry worldwide. Users can record, save, evaluate and transfer their results via Smartphone and tablet PC in order to monitor their own health. The customer base is enormous and growing considering Apple, selling 37 million iPhones in the fourth quarter of 2011 alone. MEDISANA AG will continue to consistently implement its corporate strategy to be one of the most innovative brands, especially in mobile health care, according to CEO Ralf Lindner. Therefore MEDISANA will continue to invest in the development of the VitaDock product range.

MEDISANA has achieved considerable relief on the cost side through the sale of Gimelli, while at the same time, their production capacities remain available on unchanged terms. This will also allow the company to now draw benefits in the classic health products area. In view of these circumstances, and in the expectation of the further growing importance of the VitaDock series, which should be particularly evident in the fourth-quarter business trend, the Management Board is assuming that it will achieve a further earnings improvement in 2012, and a return to operating profitability.

Forthcoming dates
07/-09/05/2012 Entry and General Standard Conference, Frankfurt am Main
19/05/2012 Publication of Group 2012 interim report within first half of 2012
26/06/2012 Ordinary Annual General Meeting, Düsseldorf
31/08/2012 Publication of H1 2012 financial report
31/08/-05/09/2012 IFA international consumer electronics and home appliances trade fair 2012, Berlin
14/-17/11/2012 Medica trade fair, Düsseldorf
19/11/2012 Publication of Group 2012 interim report within second half of 2012

MEDISANA AG
Jagenbergstrasse 19, 41468 Neuss
Tel.: +49 (0) 2131 / 36 68 0
Fax: +49 (0) 2131 / 36 68 50 95
Email:info@medisana.de
www.medisana.de

UBJ. GmbH
Kapstadtring 10, 22297 Hamburg
T.: +49 (0) 40 6378 5410
F.: +49 (0) 40 6378 5423
ir@ubj.de
www.ubj.de